Presentation is loading. Please wait.

Presentation is loading. Please wait.

The Latest Prescription Trends for Controlled Prescription Drugs

Published byZoe Horton Modified over 8 years ago

Similar presentations

Presentation on theme: "The Latest Prescription Trends for Controlled Prescription Drugs"— Presentation transcript:

1 The Latest Prescription Trends for Controlled Prescription Drugs
September 1, 2015 Christopher M. Jones PharmD, MPH Senior Advisor Office of Public Health Strategy and Analysis Office of the Commissioner Food and Drug Administration

2 Overview Data source Opioid analgesics Benzodiazepines Stimulants
Opioid use disorder medication assisted treatments Conclusions

3 Data Source Data from IMS Health National Prescription Audit
National Prescription Audit Extended Insights

4 Opioid Analgesics

5 Opioid analgesic prescriptions dispensed from US retail pharmacies, Q42009-Q22015
Source: IMS Health National Prescription Audit, Data Extracted 8/24/2015

6 Opioid analgesic prescriptions dispensed from US retail pharmacies for select opioids, Q42009-Q22015
% of All Opioids Dispensed in Q2-2015 40.8% 24.6% 17.8 3.7% 2.2% Source: IMS Health National Prescription Audit, Data Extracted 8/24/2015

7 Opioid analgesic prescriptions dispensed from US retail pharmacies by provider specialty, 2010-2014
Source: IMS Health National Prescription Audit, Data Extracted 8/24/2015

8 Percentage of opioid analgesic prescriptions dispensed from US retail pharmacies by specialty, 2010 vs 2014 Source: IMS Health National Prescription Audit, Data Extracted 8/24/2015

9 Opioid analgesic prescriptions dispensed from US retail pharmacies by gender, August 2014-July 2015
Source: IMS Health National Prescription Audit Extended Insights Data Extracted 8/24/2015

10 Opioid analgesic prescriptions dispensed from US retail pharmacies by age group, August 2014-July 2015 Source: IMS Health National Prescription Audit Extended Insights Data Extracted 8/24/2015

11 Benzodiazepines

12 Benzodiazepine prescriptions dispensed from US retail pharmacies, Q42009-Q22015
Source: IMS Health National Prescription Audit, Data Extracted 8/24/2015

13 Benzodiazepine prescriptions dispensed from US retail pharmacies by provider specialty, 2010-2014
Source: IMS Health National Prescription Audit, Data Extracted 8/24/2015

14 Percentage of benzodiazepine prescriptions dispensed from US retail pharmacies by specialty, 2010 vs 2014 Source: IMS Health National Prescription Audit, Data Extracted 8/24/2015

15 Benzodiazepine prescriptions dispensed from US retail pharmacies by gender, August 2014-July 2015
Source: IMS Health National Prescription Audit Extended Insights Data Extracted 8/24/2015

16 Benzodiazepine prescriptions dispensed from US retail pharmacies by age group, August 2014-July 2015
Source: IMS Health National Prescription Audit Extended Insights Data Extracted 8/24/2015

17 STimulants

18 Stimulant* prescriptions dispensed from US retail pharmacies, Q42009-Q22015
* includes: amphetamine, amphetamine-dextroamphetamine, dextroamphetamine,, dexmethylphenidate, lisdexamfetamine, methamphetamine, methylphenidate, pemoline Source: IMS Health National Prescription Audit, Data Extracted 8/24/2015

19 Stimulant* prescriptions dispensed from US retail pharmacies by provider specialty, 2010-2014
* includes: amphetamine, amphetamine-dextroamphetamine, dextroamphetamine,, dexmethylphenidate, lisdexamfetamine, methamphetamine, methylphenidate, pemoline Source: IMS Health National Prescription Audit, Data Extracted 8/24/2015

20 Percentage of stimulant
Percentage of stimulant* prescriptions dispensed from US retail pharmacies by specialty, vs 2014 * includes: amphetamine, amphetamine-dextroamphetamine, dextroamphetamine,, dexmethylphenidate, lisdexamfetamine, methamphetamine, methylphenidate, pemoline Source: IMS Health National Prescription Audit, Data Extracted 8/24/2015

21 Stimulant* prescriptions dispensed from US retail pharmacies by gender, August 2014-July 2015
*includes: amphetamine, amphetamine-dextroamphetamine, dextroamphetamine,, dexmethylphenidate, lisdexamfetamine, methamphetamine, methylphenidate, Pemoline, modafinil, armodafinil, caffeine, Source: IMS Health National Prescription Audit Extended Insights Data Extracted 8/24/2015

22 Stimulant* prescriptions dispensed from US retail pharmacies by age group, August 2014-July 2015
*includes: amphetamine, amphetamine-dextroamphetamine, dextroamphetamine,, dexmethylphenidate, lisdexamfetamine, methamphetamine, methylphenidate, Pemoline, modafinil, armodafinil, caffeine, Source: IMS Health National Prescription Audit Extended Insights Data Extracted 8/24/2015

23 Opioid use disorder medication assisted treatments

24 Buprenorphine* prescriptions dispensed from US retail pharmacies, Q42009-Q22015
*Does not include Butrans or Buprenex (or generics) Source: IMS Health National Prescription Audit, Data Extracted 8/24/2015

25 Percentage of buprenorphine
Percentage of buprenorphine* prescriptions dispensed from US retail pharmacies by specialty, vs 2014 *Does not include Butrans or Buprenex (or generics) Source: IMS Health National Prescription Audit, Data Extracted 8/24/2015

26 Naltrexone* prescriptions dispensed from US retail pharmacies, Q42009-Q22015
+ * Naltrexone is also approved for use in alcohol dependence. Thus, not all prescriptions were used for opioid dependence +The number of prescriptions dispensed for Vivitrol from specialty pharmacies is approximately 3-4x that from US retail pharmacies. Source: IMS Health National Prescription Audit, Data Extracted 8/24/2015

27 Percentage of naltrexone
Percentage of naltrexone* prescriptions dispensed from US retail pharmacies+ by specialty, vs 2014 * Naltrexone is also approved for use in alcohol dependence. Thus, not all prescriptions were used for opioid dependence +The number of prescriptions dispensed for Vivitrol from specialty pharmacies is approximately 3-4x that from US retail pharmacies. Source: IMS Health National Prescription Audit, Data Extracted 8/24/2015

28 Conclusions The number of prescriptions dispensed for opioid analgesics has declined in recent years The number of prescriptions dispensed for benzodiazepines has been relatively consistent The number of prescriptions dispensed for stimulants has increased in recent years The number of prescriptions dispensed for both naltrexone and buprenorphine has increased in recent years There is variation in prescribing by provider specialty and patient gender and age across the examined drug classes

29 Questions. Christopher. M. Jones@fda. hhs
Questions? The findings in this presentation do not represent the official position of the US Food and Drug Administration, the Department of Health and Human Services, or the U.S. Government

Download ppt "The Latest Prescription Trends for Controlled Prescription Drugs"

Similar presentations

Cindy Powers Magrini, PharmD, BCPS

Cindy Powers Magrini, PharmD, BCPS
Medication Assisted Treatment in Missouri Mark Stringer, Director Missouri Divisions of Alcohol and Drug Abuse & Comprehensive Psychiatric Services NASADAD.

Medication Assisted Treatment in Missouri Mark Stringer, Director Missouri Divisions of Alcohol and Drug Abuse & Comprehensive Psychiatric Services NASADAD.
Stimulant Prescribing Training Guide Completion of a ‘Notification of Treatment using Stimulant Medication’ form.

Stimulant Prescribing Training Guide Completion of a ‘Notification of Treatment using Stimulant Medication’ form.
A Growing Problem…. We Will Discuss Prescription vs. OTC medications Alarming trends Myths about prescription drug abuse Specific medications of abuse.

A Growing Problem…. We Will Discuss Prescription vs. OTC medications Alarming trends Myths about prescription drug abuse Specific medications of abuse.
Ambulatory Treatment of Type 2 Diabetes in the U.S., 1997–2012 Featured Article: Lydia W. Turner, David Nartey, Randall S. Stafford, Sonal Singh, and G.

Ambulatory Treatment of Type 2 Diabetes in the U.S., 1997–2012 Featured Article: Lydia W. Turner, David Nartey, Randall S. Stafford, Sonal Singh, and G.
CDER/CSS ALSDAC September 9-10, 2003 Risk Management and the Controlled Substances Act: The FDA Perspective Deborah B. Leiderman, M.D., M.A. Director Controlled.

CDER/CSS ALSDAC September 9-10, 2003 Risk Management and the Controlled Substances Act: The FDA Perspective Deborah B. Leiderman, M.D., M.A. Director Controlled.
OVERDOSE SOLUTIONS 2013 OVERDOSE DATA FOR ALLEGHENY COUNTY Jennifer Janssen Manager Toxicology Laboratory Allegheny County Office of the Medical Examiner.

OVERDOSE SOLUTIONS 2013 OVERDOSE DATA FOR ALLEGHENY COUNTY Jennifer Janssen Manager Toxicology Laboratory Allegheny County Office of the Medical Examiner.
Sublingual Buprenorphine and Pain

Sublingual Buprenorphine and Pain
Innovations: Using a Clinical Pharmacist as a Vehicle for Successful P4P Outcomes Lisa Meland, B.S., PharmD. Helen Pervanas, R.Ph. WellPoint-WellPoint.

Innovations: Using a Clinical Pharmacist as a Vehicle for Successful P4P Outcomes Lisa Meland, B.S., PharmD. Helen Pervanas, R.Ph. WellPoint-WellPoint.
Anesthetic and Life Support Drugs, and Drug Safety and Risk Management Advisory Committees, November 13, 2008 Outpatient Drug Utilization Trends for Oxycodone.

Anesthetic and Life Support Drugs, and Drug Safety and Risk Management Advisory Committees, November 13, 2008 Outpatient Drug Utilization Trends for Oxycodone.
1 Drug Utilization for Immediate- and Modified Release Opioids in the U.S. Gianna C. Rigoni, Pharm.D., M.S. Epidemiologist Division of Surveillance, Research.

1 Drug Utilization for Immediate- and Modified Release Opioids in the U.S. Gianna C. Rigoni, Pharm.D., M.S. Epidemiologist Division of Surveillance, Research.
Controlled Substance Prescribing Trends and Physician and Pharmacy Utilization Patterns: Epidemiological Analysis of the Maine Prescription Monitoring.

Controlled Substance Prescribing Trends and Physician and Pharmacy Utilization Patterns: Epidemiological Analysis of the Maine Prescription Monitoring.
John R. Kasich, Governor Tracy J. Plouck, Director Andrea Boxill, Deputy Director Andrea Boxill, Deputy Director Governor’s Cabinet Opiate Action Team.

John R. Kasich, Governor Tracy J. Plouck, Director Andrea Boxill, Deputy Director Andrea Boxill, Deputy Director Governor’s Cabinet Opiate Action Team.
® © 2013 National Safety Council Prevention: Teen Abuse of Prescription Drugs Support for this project was provided by the U.S. Department of Health and.

® © 2013 National Safety Council Prevention: Teen Abuse of Prescription Drugs Support for this project was provided by the U.S. Department of Health and.
Prescription Opioid Use and Opioid-Related Overdose Death — TN, 2009–2010 Jane A.G. Baumblatt, MD Centers for Disease Control and Prevention Epidemic Intelligence.

Prescription Opioid Use and Opioid-Related Overdose Death — TN, 2009–2010 Jane A.G. Baumblatt, MD Centers for Disease Control and Prevention Epidemic Intelligence.
Drug Safety and Risk Management Advisory Committee February 9, 2006 Overview of ADHD and its Pharmacotherapy Andrew D. Mosholder, M.D., M.P.H. FDA Division.

Drug Safety and Risk Management Advisory Committee February 9, 2006 Overview of ADHD and its Pharmacotherapy Andrew D. Mosholder, M.D., M.P.H. FDA Division.
Abuse Liability of Hydromorphone Extended Release Capsules Silvia N. Calderon, Ph.D. Controlled Substance Staff Center for Drug Evaluation and Research.

Abuse Liability of Hydromorphone Extended Release Capsules Silvia N. Calderon, Ph.D. Controlled Substance Staff Center for Drug Evaluation and Research.
Slide 1 Overview of the Drug Formulary Commission and Statutory Objectives Bureau of Health Care Safety and Quality Department of Public Health August.

Slide 1 Overview of the Drug Formulary Commission and Statutory Objectives Bureau of Health Care Safety and Quality Department of Public Health August.
Center for Drug Evaluation and Research Patterns of Prescription Weight-Loss Drug Use Endocrinologic and Metabolic Drugs Advisory Committee Meeting Rockville,

Center for Drug Evaluation and Research Patterns of Prescription Weight-Loss Drug Use Endocrinologic and Metabolic Drugs Advisory Committee Meeting Rockville,
1 One Year Post Exclusivity Adverse Event Review: Ofloxacin Ophthalmic Pediatric Advisory Committee Meeting September 15, 2004 Hari Cheryl Sachs, MD, FAAP.

1 One Year Post Exclusivity Adverse Event Review: Ofloxacin Ophthalmic Pediatric Advisory Committee Meeting September 15, 2004 Hari Cheryl Sachs, MD, FAAP.

Similar presentations

Ads by Google